Short answer
CERUS CORP (CERS) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $58M with net income of −$550,000.
Q3 2026 key financials · XBRL
- Revenue
- $58M
- +0.5% QoQ
- Net income
- −$550,000
- −2794.7% YoY · +81.3% QoQ
- Operating margin
- 0.7%
- EPS (diluted)
- −$0.01
- +0.0% QoQ
Source: XBRL data from the CERUS CORP (CERS) Q3 2026 10-Q on SEC EDGAR. USD.
CERUS CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $64.018M, up $3.781M YoY, driven by platelet kits, IFC sales and EMEA LED illuminators
- Product gross margin 52% vs 53% YoY, pressured by foreign exchange, inventory costs and tariffs
- Product revenue $57.714M, up $5.016M, while government contract revenue fell $1.235M to $6.304M
- Cash, investments and restricted cash $57.734M vs $83.518M at December 31, 2025
- Near-term headwinds: tariffs, conflicts, supply-chain disruption and potential reductions or delays in BARDA funding
Risk Factors
- New regulatory risk: EU EUDAMED modules become mandatory May 28, 2026, increasing compliance costs
- BARDA funding risk: 2016 Agreement options discontinued, while 2024 Agreement potential funding increased to $209.0 million
- Regulatory approval risk: ANSM review continues for the red blood cell system’s MDR application after prior closure
- Market risk: U.S. platelet shortages may reduce demand for INTERCEPT-treated products despite safety-compliance options
- Customer concentration risk: American Red Cross represents the largest single portion of U.S. blood collection market
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CERUS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.